Decreasing chemokines like CXCL10, known trigger the first auto- or alloimmune response, and CXCL8, present since early stages of inflammation and remaining active for long time (95), before clinical manifestations - i.e., at stages A or B, according to American Heart Association/American College of Cardiology (AHA/ACC) classification (https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-of-heart-failure) - might be of clinically relevant impact, as it could attenuate downstream inflammatory cascade and progression to HF. The gene discussed is CXCL8; the disease is heart failure.